Abstract:Background and Aim: Glioma is one of the most prevalent and refractory brain cancers with a high recurrence rate. Current limitations of experimental in vitro models include their inability to remodel the heterogeneity of the parental tumors and their incapacity to effectively reflect antitumor effects and mechanisms observable in vivo. Organoid models, as a new technology developed in recent years, can preserve the histological characteristics, cellular diversity, and gene expression of parental tumors to the fullest extent, thereby delivering more reliable data. This study intends to construct a simple organoid model developed from glioma patient material. Materials and Methods: Glioma samples were taken intraoperatively and cultured in the organoid medium using a continuous horizontal shaker. Sample collection and scientific research were authorized and approved by the Ethics Committee of Kowloon Hospital, China (Approval No. KY-2021-007). Immunofluorescence was applied to identify CD31 and Sox2 protein expression in the organoid model. The differences between primary glioblastomas and transplanted organoid tumors were analyzed by hematoxylin and eosin (H and E) staining. Immunohistochemistry (IHC) and Western blot assay were used to analyze the Sox2, Ki67, and CD31 protein expression levels. Results: The success rate of establishing organoid models was 90.9% in the primary glioblastomas, 75.0% in the WHO Grade III gliomas, and 42.9% in the Grade I–II gliomas. Immunofluorescence demonstrated that in vitro cultured organoids expressed CD31 and Sox2. Similarly, IHC and Western blot assay showed that orthotopically transplanted organoid tumors could exhibit high expressions of Sox2, Ki67, and CD31. There were no significant differences regarding the pathological features of primary glioblastomas and glioma organoid model as judged by H and E staining. Conclusions: This study presents a simple in vitro organoid model established from glioma patient samples. The success rate of constructing an organoid model is correlated with the degree of glioma malignancy. The established organoid model displays original model properties and simplifies the development of new experimental platforms that can support preclinical glioma treatment studies.

Generating Patient-Derived Gliomas within Cerebral Organoids

Modeling glioblastoma tumor progression via CRISPR-engineered brain organoids

Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy

Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications

Tmic-34. Infiltrative Behavior Of Patient-Derived Glioblastoma Cell Lines In Region-Specific Human Brain Organoids

Organoid Models of Glioblastoma: Advances, Applications and Challenges

Glioblastoma organoid technology: an emerging preclinical models for drug discovery

Spontaneous Glioblastoma Spheroid Infiltration of Early-Stage Cerebral Organoids Models Brain Tumor Invasion

Protocol for Generating in Vitro Glioma Models Using Human-Induced Pluripotent- or Embryonic-Stem-cell-derived Cerebral Organoids.

Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing

The Advancements of Organoids Push the Boundaries of Glioblastoma Research

The generation of glioma organoids and the comparison of two culture methods

Establishment of Patient-Derived Organoid Models of Lower-Grade Glioma.

Establishment and Validation of Glioma Patient-Derived Organoid Models

TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro

A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening

Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity

Patient-derived organoids recapitulate glioma-intrinsic immune program and progenitor populations of glioblastoma

MODL-04. ESTABLISHMENT OF A RELIABLE GLIOBLASTOMA TUMOR-ORGANOID PLATFORM ENABLES AUTOMATED HIGH-THROUGHPUT DRUG SCREENING ADVANCING PERSONALIZED MEDICINE

The Comparison Genomics Analysis with Glioblastoma Multiforme (GBM) Cells under 3D and 2D Cell Culture Conditions

Tmod-34. Generation Of Brain-Vessel-Gbm Assembloids Using Patient-Derived Glioblastoma Tissue